VR Logo

Glaukos Corporation (GKOS) download report


Healthcare | Medical Devices & Equipment

Glaukos Corporation (GKOS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

IPO Date: 25-Jun-2015

Chairman & CEO: Mr. Thomas William Burns

Pres & COO: Mr. Joseph E. Gilliam

Listing: NYSE: GKOS

Country: United States

Headquarters: San Clemente, CA

Website: https://www.glaukos.com

Key Facts

Market cap: $2,137.82 Mln

Revenue (TTM): $293.72 Mln

Earnings (TTM): $-27.75 Mln

Cash: $415.41 Mln

Total Debt: $382.27 Mln

Insider's Holding: 3.88%

Liquidity: Low

52 Week range: $33.33 - 87.18

Shares outstanding: 47,333,600

9 Years Aggregate:

  • CFO: $35.43 Mln
  • EBITDA: $-163.40 Mln
  • Net Profit: $-225.04 Mln

Stock Performance

Time Period Glaukos (GKOS) S&P BSE Sensex S&P Small-Cap 600
YTD6.35-9.49-17.79
1 month16.84-2.87-2.72
3 months-14.17-8.59-12.17
1 Year-45.280.81-15.82
3 Years-14.5110.397.14
5 Years1.3311.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Glaukos (GKOS) S&P Small-Cap 600 S&P BSE Sensex
2021-40.9525.2721.99
202038.179.5715.75
2019-3.0320.8614.38
2018118.05-9.705.87
2017-25.2211.7327.91
201638.9224.741.95